SEP 11, 2018 08:21 PM PDT

Potential Non-Antibiotic Drug For Tuberculosis

WRITTEN BY: Nouran Amin

Credit: Image via Homeopathy Plus (homeopathyplus.com)

After 10 years of research, scientists at the University of Manchester have created the first non-antibiotic drug that can successfully treat tuberculosis (TB) in animal models. The research, which was funded by the Medical Research Council, was published in the Journal of Medicinal Chemistry. The scientists hope that the developed drug will enter clinical trials within the next three to four years.

The drug works by targeting the Mycobacterium tuberculosis’ defense system rather than attacking the bacterium itself, possibly taking out the common antibiotic-resistant strain. Even though 100 years earlier, a vaccine was created for TB, still today one in three people across the globe are thought to be infected. Roughly 1.7 million worldwide die annually from TB, however, about 7.3 million of those diagnosed with TB were treated in 2018.

The infectious disease is most prevalent in Africa, India, and China. However, it has been recently on the rise in the UK with London often labeled as the “TB capital of Europe”. Those diagnosed with TB often are prescribed a series of strong antibiotics over the course of 6 to 8 months while withstanding adverse side effects including a 20% risk of the disease returning.

Now, the developed drug was proven effective in rodents at Rutgers University. "The fact that the animal studies showed our compound, which doesn't kill the bacteria directly, resulted in a significant reduction in the bacterial burden is remarkable,” explains project leader Professor Lydia Tabernero. “For more than 60 years, the only weapon doctors have been able to use against TB is antibiotics. But resistance is becoming an increasingly worrying problem and the prolonged treatment is difficult and distressing for patients. And with current treatments, there's no guarantee the disease will be eliminated: antibiotics do not clear the infection and the risk of being infected with drug-resistant bacteria is very high. But by disabling this clandestine bacteria's defenses we're thrilled to find a way that enhances the chances of the body's immune system to do its job, and thus eliminates the pathogen."

The bacterium responsible for tuberculosis produces molecules known as Virulence Factors which help inhibit the immune response to the infection. One Virulence Factor that was identified is called MptpB. MptpB is a drug suitable target because when inhibited, it allows the white blood cells (leukocytes) to kill the Mycobacterium effectively. "The great thing about MptpB is that there's nothing similar in humans -- so our compound which blocks it is not toxic to the human cells,” explains Tabernero. "Because the bacteria hasn't been threatened directly, it is less likely to develop resistance against this new agent, and this will be a major advantage over current antibiotics, for which bacteria had already become resistant. TB is an amazingly difficult disease to treat so we feel this is a significant breakthrough. The next stage of our research is to optimize further the chemical compound, but we hope Clinical trials are up to four years away."

To learn more about Tuberculosis, watch the video below!

Source: University of Manchester

About the Author
  • Nouran enjoys writing on various topics including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
SEP 24, 2018
Drug Discovery
SEP 24, 2018
Natural Antibiotic Effective for Drug-Resistant Tuberculosis
A paper published in journal Molecular Cell, describes a naturally occurring antibiotic known as kanglemycin A which is related to the antibiotic rifampici...
OCT 16, 2018
Drug Discovery
OCT 16, 2018
Anti-Venomous Plant Compound
According to a study published in PLOS Neglected Tropical Diseases, researchers at the Institute Butantan, São Paulo, Brazil, have discovered a flav...
NOV 05, 2018
Drug Discovery
NOV 05, 2018
Drug Combination Halts The Progression of Fibrosis
After seven years of research, scientists at Anglia Ruskin University, University College London and KU Leuven—developed a drug combination that hold...
NOV 15, 2018
Drug Discovery
NOV 15, 2018
Making Cancer Disappear?
Neuroblastoma is one of the most common childhood cancers and the leading cause of cancer deaths among pediatric patients younger than 5. The cancer is fre...
NOV 21, 2018
Microbiology
NOV 21, 2018
Human Antibody That can Neutralize West Nile Virus is Found
In 1999, there were 62 cases of West Nile Virus in New York State. Since then it has spread around the United States....
JAN 14, 2019
Drug Discovery
JAN 14, 2019
Vitamin D Proved Non-Beneficial for Individuals Aged 70 and Over
According to a study in the American Journal of Clinical Nutrition, researchers at Newcastle University have confirmed that older individuals, over the age...
Loading Comments...